- FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with heart failure with preserved ejection fraction, which has been classified as "the single largest ...
Key secondary outcomes include cardiovascular death or hospitalization for heart failure, all-cause hospitalization and all-cause mortality. EMPA-KIDNEY includes 6,609 adults randomized from eight ...
The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once ...
Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance ® (empagliflozin) 10 mg tablets significantly reduced the risk ...
Eli Lilly LLY announced that the FDA has expanded the label of its diabetes drug, Jardiance (empagliflozin), to chronic kidney disease (“CKD”). Jardiance is now approved in the United States to reduce ...
Gearing up for the launch of diabetes and heart failure drug Jardiance in chronic kidney disease, Boehringer Ingelheim has already started 2023 by posting strong pharma sales growth. The German ...
The Food and Drug Administration approved Eli Lilly’s Jardiance (empagliflozin) for treating adults with chronic kidney disease (CKD) on Friday morning. The agency approved 10 mg tablets of Jardiance ...
Please provide your email address to receive an email when new articles are posted on . Jardiance had a 28% relative risk reduction for kidney disease progression vs. placebo. The drug also showed a ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg tablets to reduce the risk of sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback